Ontology highlight
ABSTRACT:
PROVIDER: PRJNA271165 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR1734360.fastq.gz | Fastqsanger.gz | |||
| SRR1734361.fastq.gz | Fastqsanger.gz | |||
| SRR1734841.fastq.gz | Fastqsanger.gz | |||
| SRR1734362.fastq.gz | Fastqsanger.gz | |||
| SRR1734842.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 10 |
Similar Datasets
Project description:Enhancer-bound LDB1 Regulates a Corticotrope Promoter Pausing Repression Program [ChIP-seq]
| PRJNA271094 | ENA
Project description:Enhancer-bound LDB1 Regulates a Corticotrope Promoter Pausing Repression Program [GRO-seq]
| PRJNA271166 | ENA
Project description:Substantial evidence supports the hypothesis that enhancers are critical regulators of cell type determination, orchestrating both positive and negative transcriptional programs; however, the basic mechanisms by which enhancers orchestrate interactions with cognate promoters during activation and repression events remain incompletely understood. Here we report the required actions of the LIM domain binding protein, LDB1/CLIM2/NLI, interacting with the enhancer binding protein, ASCL1, to mediate looping to target gene promoters and target gene regulation in corticotrope cells. LDB1-mediated enhancer:promoter looping appears to be required for both activation and repression of these target target gene promoter genes. While LDB1-dependend activated genes are regulated at the level of transcriptional initiation, the LDB1-dependent repressed transcription units appear to be regulated primarily at the level of promoter pausing, with LDB1 regulating recruitment of MTA2, a component of the NuRD complex, on these negative enhancers, required for the repressive enhancer function. These results indicate that LDB1-dependent looping events can deliver repressive cargo to cognate promoters to mediate promoter pausing events in a pituitary cell type. ChIP assay followed by high throughput sequencing (ChIP-seq)
2015-02-03 | E-GEOD-64483 | biostudies-arrayexpress
Project description:Substantial evidence supports the hypothesis that enhancers are critical regulators of cell type determination, orchestrating both positive and negative transcriptional programs; however, the basic mechanisms by which enhancers orchestrate interactions with cognate promoters during activation and repression events remain incompletely understood. Here we report the required actions of the LIM domain binding protein, LDB1/CLIM2/NLI, interacting with the enhancer binding protein, ASCL1, to mediate looping to target gene promoters and target gene regulation in corticotrope cells. LDB1-mediated enhancer:promoter looping appears to be required for both activation and repression of these target target gene promoter genes. While LDB1-dependend activated genes are regulated at the level of transcriptional initiation, the LDB1-dependent repressed transcription units appear to be regulated primarily at the level of promoter pausing, with LDB1 regulating recruitment of MTA2, a component of the NuRD complex, on these negative enhancers, required for the repressive enhancer function. These results indicate that LDB1-dependent looping events can deliver repressive cargo to cognate promoters to mediate promoter pausing events in a pituitary cell type. Global Run On (GRO) assay followed by high throughput sequencing (GRO-seq)
2015-02-03 | E-GEOD-64515 | biostudies-arrayexpress
Project description:Substantial evidence supports the hypothesis that enhancers are critical regulators of cell type determination, orchestrating both positive and negative transcriptional programs; however, the basic mechanisms by which enhancers orchestrate interactions with cognate promoters during activation and repression events remain incompletely understood. Here we report the required actions of the LIM domain binding protein, LDB1/CLIM2/NLI, interacting with the enhancer binding protein, ASCL1, to mediate looping to target gene promoters and target gene regulation in corticotrope cells. LDB1-mediated enhancer:promoter looping appears to be required for both activation and repression of these target target gene promoter genes. While LDB1-dependend activated genes are regulated at the level of transcriptional initiation, the LDB1-dependent repressed transcription units appear to be regulated primarily at the level of promoter pausing, with LDB1 regulating recruitment of MTA2, a component of the NuRD complex, on these negative enhancers, required for the repressive enhancer function. These results indicate that LDB1-dependent looping events can deliver repressive cargo to cognate promoters to mediate promoter pausing events in a pituitary cell type.
2015-02-03 | GSE64483 | GEO
Project description:Substantial evidence supports the hypothesis that enhancers are critical regulators of cell type determination, orchestrating both positive and negative transcriptional programs; however, the basic mechanisms by which enhancers orchestrate interactions with cognate promoters during activation and repression events remain incompletely understood. Here we report the required actions of the LIM domain binding protein, LDB1/CLIM2/NLI, interacting with the enhancer binding protein, ASCL1, to mediate looping to target gene promoters and target gene regulation in corticotrope cells. LDB1-mediated enhancer:promoter looping appears to be required for both activation and repression of these target target gene promoter genes. While LDB1-dependend activated genes are regulated at the level of transcriptional initiation, the LDB1-dependent repressed transcription units appear to be regulated primarily at the level of promoter pausing, with LDB1 regulating recruitment of MTA2, a component of the NuRD complex, on these negative enhancers, required for the repressive enhancer function. These results indicate that LDB1-dependent looping events can deliver repressive cargo to cognate promoters to mediate promoter pausing events in a pituitary cell type.
2015-02-03 | GSE64515 | GEO
Project description:Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a five-year survival rate of 12%. It has two major molecular subtypes: classical and basal, regulated by the master transcription factors (MTFs) GATA6 and ΔNp63, respectively. This study aims to uncover the transcriptional regulatory mechanisms controlling PDAC subtype identity. We integrated primary tumor single-cell RNA-seq, patient-derived xenograft RNA-seq, and multispectral imaging to identify MTF-dependent, subtype-specific markers. We created subtype-specific fluorescent reporter systems and conducted drug screenings to find actionable targets. We analyzed genome-wide occupancy (ChIP-seq) for epigenetic status (H3K27ac), MTFs (GATA6, ΔNp63), RNA polymerase II (Pol II), nascent RNA capture sequencing (PRO-seq), and H3K4me3-anchored chromatin topology (HiChIP). Additionally, we used nuclease-dead Cas9 (dCas9) to manipulate transcriptional regulatory mechanisms. Our approach identified glucocorticoid receptor (GR) agonists as agents that suppress the classical transcriptional program by modulating GATA6 activity. GATA6 regulates classical-specific transcription through promoter-proximal pause (PPP) release. Depletion of GATA6 increased Pol II occupancy at GATA6-bound enhancers and transcriptional start sites, stabilizing enhancer-promoter interactions. Artificially inducing pausing at GATA6-bound enhancers with dCas9 abrogated target gene expression and induced pausing at both the enhancer and target gene promoter. Conversely, ΔNp63 in basal PDAC promotes Pol II recruitment and stabilizes enhancer-promoter interactions. This study provides new insights into the transcriptional control of PDAC subtypes and suggests potential therapeutic strategies, highlighting the role of glucocorticoids in PDAC chemotherapy.
2025-01-07 | GSE271732 | GEO
Project description:Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a five-year survival rate of 12%. It has two major molecular subtypes: classical and basal, regulated by the master transcription factors (MTFs) GATA6 and ΔNp63, respectively. This study aims to uncover the transcriptional regulatory mechanisms controlling PDAC subtype identity. We integrated primary tumor single-cell RNA-seq, patient-derived xenograft RNA-seq, and multispectral imaging to identify MTF-dependent, subtype-specific markers. We created subtype-specific fluorescent reporter systems and conducted drug screenings to find actionable targets. We analyzed genome-wide occupancy (ChIP-seq) for epigenetic status (H3K27ac), MTFs (GATA6, ΔNp63), RNA polymerase II (Pol II), nascent RNA capture sequencing (PRO-seq), and H3K4me3-anchored chromatin topology (HiChIP). Additionally, we used nuclease-dead Cas9 (dCas9) to manipulate transcriptional regulatory mechanisms. Our approach identified glucocorticoid receptor (GR) agonists as agents that suppress the classical transcriptional program by modulating GATA6 activity. GATA6 regulates classical-specific transcription through promoter-proximal pause (PPP) release. Depletion of GATA6 increased Pol II occupancy at GATA6-bound enhancers and transcriptional start sites, stabilizing enhancer-promoter interactions. Artificially inducing pausing at GATA6-bound enhancers with dCas9 abrogated target gene expression and induced pausing at both the enhancer and target gene promoter. Conversely, ΔNp63 in basal PDAC promotes Pol II recruitment and stabilizes enhancer-promoter interactions. This study provides new insights into the transcriptional control of PDAC subtypes and suggests potential therapeutic strategies, highlighting the role of glucocorticoids in PDAC chemotherapy.
2025-01-07 | GSE271731 | GEO
Project description:Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a five-year survival rate of 12%. It has two major molecular subtypes: classical and basal, regulated by the master transcription factors (MTFs) GATA6 and ΔNp63, respectively. This study aims to uncover the transcriptional regulatory mechanisms controlling PDAC subtype identity. We integrated primary tumor single-cell RNA-seq, patient-derived xenograft RNA-seq, and multispectral imaging to identify MTF-dependent, subtype-specific markers. We created subtype-specific fluorescent reporter systems and conducted drug screenings to find actionable targets. We analyzed genome-wide occupancy (ChIP-seq) for epigenetic status (H3K27ac), MTFs (GATA6, ΔNp63), RNA polymerase II (Pol II), nascent RNA capture sequencing (PRO-seq), and H3K4me3-anchored chromatin topology (HiChIP). Additionally, we used nuclease-dead Cas9 (dCas9) to manipulate transcriptional regulatory mechanisms. Our approach identified glucocorticoid receptor (GR) agonists as agents that suppress the classical transcriptional program by modulating GATA6 activity. GATA6 regulates classical-specific transcription through promoter-proximal pause (PPP) release. Depletion of GATA6 increased Pol II occupancy at GATA6-bound enhancers and transcriptional start sites, stabilizing enhancer-promoter interactions. Artificially inducing pausing at GATA6-bound enhancers with dCas9 abrogated target gene expression and induced pausing at both the enhancer and target gene promoter. Conversely, ΔNp63 in basal PDAC promotes Pol II recruitment and stabilizes enhancer-promoter interactions. This study provides new insights into the transcriptional control of PDAC subtypes and suggests potential therapeutic strategies, highlighting the role of glucocorticoids in PDAC chemotherapy.
2025-01-07 | GSE272796 | GEO
Project description:Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a five-year survival rate of 12%. It has two major molecular subtypes: classical and basal, regulated by the master transcription factors (MTFs) GATA6 and ΔNp63, respectively. This study aims to uncover the transcriptional regulatory mechanisms controlling PDAC subtype identity. We integrated primary tumor single-cell RNA-seq, patient-derived xenograft RNA-seq, and multispectral imaging to identify MTF-dependent, subtype-specific markers. We created subtype-specific fluorescent reporter systems and conducted drug screenings to find actionable targets. We analyzed genome-wide occupancy (ChIP-seq) for epigenetic status (H3K27ac), MTFs (GATA6, ΔNp63), RNA polymerase II (Pol II), nascent RNA capture sequencing (PRO-seq), and H3K4me3-anchored chromatin topology (HiChIP). Additionally, we used nuclease-dead Cas9 (dCas9) to manipulate transcriptional regulatory mechanisms. Our approach identified glucocorticoid receptor (GR) agonists as agents that suppress the classical transcriptional program by modulating GATA6 activity. GATA6 regulates classical-specific transcription through promoter-proximal pause (PPP) release. Depletion of GATA6 increased Pol II occupancy at GATA6-bound enhancers and transcriptional start sites, stabilizing enhancer-promoter interactions. Artificially inducing pausing at GATA6-bound enhancers with dCas9 abrogated target gene expression and induced pausing at both the enhancer and target gene promoter. Conversely, ΔNp63 in basal PDAC promotes Pol II recruitment and stabilizes enhancer-promoter interactions. This study provides new insights into the transcriptional control of PDAC subtypes and suggests potential therapeutic strategies, highlighting the role of glucocorticoids in PDAC chemotherapy.
2025-01-07 | GSE271737 | GEO